Drug Profile
BMS 247615
Alternative Names: TAS-103Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Taiho Pharmaceutical
- Developer Bristol-Myers Squibb; Taiho Pharmaceutical
- Class Antineoplastics
- Mechanism of Action DNA topoisomerase I inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 22 Dec 2010 Phase-I clinical trials in Solid tumours in USA (IV)
- 09 Oct 2006 Discontinued - Phase-I for Solid tumours in Japan (IV-infusion)